adalimumab-atto 20 MG per 0.4 ML Prefilled Syringe

RxCUI: 2627711
RxNorm name: adalimumab-atto 20 MG per 0.4 ML Prefilled Syringe
Display name: adalimumab-atto 20 MG per 0.4 ML Prefilled Syringe
Full name: adalimumab-atto 20 MG per 0.4 ML Prefilled Syringe
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:39:10

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761024	Amjevita	adalimumab-atto	351(k) Interchangeable	Rx	2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
AMJEVITA	ADALIMUMAB-ATTO	Amgen, Inc	9c44bd5b-4464-40a4-8933-8680950f00f2	2026-06-25	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2627711

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
9c44bd5b-4464-40a4-8933-8680950f00f2	adalimumab-atto 20 MG per 0.4 ML Prefilled Syringe	SY	35	These highlights do not include all the information needed to use AMJEVITA safely and effectively. See full prescribing information for AMJEVITA. AMJEVITA ® (adalimumab-atto) injection, for subcutaneous use Initial U.S. Approval: 2016 AMJEVITA (adalimumab-atto) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences b	20260310
9c44bd5b-4464-40a4-8933-8680950f00f2	adalimumab-atto 20 MG in 0.4 ML Prefilled Syringe	PSN	35	These highlights do not include all the information needed to use AMJEVITA safely and effectively. See full prescribing information for AMJEVITA. AMJEVITA ® (adalimumab-atto) injection, for subcutaneous use Initial U.S. Approval: 2016 AMJEVITA (adalimumab-atto) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences b	20260310
9c44bd5b-4464-40a4-8933-8680950f00f2	0.4 ML adalimumab-atto 50 MG/ML Prefilled Syringe	SCD	35	These highlights do not include all the information needed to use AMJEVITA safely and effectively. See full prescribing information for AMJEVITA. AMJEVITA ® (adalimumab-atto) injection, for subcutaneous use Initial U.S. Approval: 2016 AMJEVITA (adalimumab-atto) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences b	20260310